1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program is sponsored by Advanced Research Projects Agency for Health (ARPA-H), U.S. Department of Health and Human Services (HHS). The ADVOCATE program aims to develop FDA-authorized, agentic AI technology to provide 24/7 specialty care for cardiovascular disease.
This includes systems that connect to patient records, assist in scheduling, provide recommendations, and support diagnoses.
Get alerted about grants like this
Save a search for “Advanced Research Projects Agency for Health (ARPA-H), U.S. Department of Health and Human Services (HHS)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Agentic AI-Enabled Cardiovascular Care Transformation What if an FDA-authorized clinical agentic AI could provide safe and effective cardiovascular care to every American?
Over 200,000 Americans die each year from preventable impacts of cardiovascular disease (CVD), the leading cause of death in the U.S. Despite spending almost half a trillion dollars on heart disease alone, the US experiences much worse outcomes than many other similar nations. Treatments for managing heart health with diet, exercise, and affordable medications are simple, inexpensive, and effective.
Yet nearly half of American counties lack a cardiologist, meaning that many patients across the country are missing out on life-saving care and interventions. Clinical artificial intelligence (AI) agents could help fill this gap, but we don’t currently have a clear way to ensure they consistently operate safely and effectively at scale in real-world settings.
The Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program aims to transform advanced cardiovascular disease management with an agentic AI system that can provide 24/7 holistic clinical care. ADVOCATE will support the development of clinical AI agents that can be trusted to autonomously adjust changes in appointments, medications, diet, and exercise.
In parallel, ADVOCATE will support the development of a supervisory AI "overseer” to monitor clinical AI agents after they have been deployed in clinical practice to ensure their continued safety and efficacy. ADVOCATE's transformative goal is to create a first-of-its-kind, reliable, FDA-authorized clinical agentic AI system that serves around the clock as a new, digital member of the clinical care team.
Together, these efforts will enable an integrated, holistic cardiovascular care platform to provide real-time guidance that patients and care teams can act on. The program will partner with health systems to successfully deploy the technology across diverse care environments—from major health systems to rural clinics and community settings.
Harness the power of American innovation to quickly develop agentic AI that is safe, transparent, and effective in healthcare settings. Unleash the best technical experts across sectors to tackle a leading cause of death in the U.S. and accelerate pathways for regulatory and reimbursement approvals.
Build trust with patients, doctors, and other stakeholders around patient-facing AI agents through rigorous testing and demonstrating measurable improvements in safety, outcomes, and equity. Pave the way for AI technology to serve as a clinician-extender, first for advanced CVD and eventually for all chronic conditions.
What ARPA-H needs to solve this problem ADVOCATE seeks leaders in the tech sector, academia, non-profit organizations, and small businesses to overcome the technical, regulatory, and market barriers holding back innovation in clinical agentic AI.
The program has three technical areas: development of a patient-facing clinical AI agent, a supervisory agent that ensures clinical AI agents’ consistent safety and effectiveness, and a scalable plan for integration into clinical workflows in healthcare organizations. Notice ID: ARPA-H-SOL-26-142 ARPA-H invites interested parties to review the solicitation, which is posted and maintained on SAM.
gov. The solicitation outlines the opportunity and its requirements, key dates and deadlines, submission documents and templates, evaluation criteria for submissions, and information on how to apply. Solution Summary Due: February 27, 2026 A summary is required to submit a full proposal.
Full Proposal Due: April 1, 2026 at 5:00PM ET After submission of a solution summary, proposers will either be encouraged or discouraged from submission of a full proposal. It is strongly recommended that only proposers who are encouraged to submit a full proposal do so. Reminder: Dates are estimates and subject to change.
Please reference the solicitation for the most up-to-date information as late submissions will not be reviewed. Review Solicitation Details Ready to apply? To submit a Solution Summary, sign-in to the ARPA-H Solutions site .
Please note: Because of significant interest in the ADVOCATE program—a signal of both the urgency of cardiovascular disease and the promise of clinical agentic AI—ADVOCATE is piloting secure large language model (LLM) tools to assist with the initial review of Solution Summaries. Read the full statement to learn more .
Frequently Asked Questions Review responses to common questions about this funding opportunity asked by others in the proposer community. You can also ask a question. Review FAQs and Ask A Question This is an optional event for the proposer community to learn more about this opportunity, ask questions, and make connections.
This event is not intended for patients, patient advocates, the media, or general interest audiences. View the Proposers' Day recording View the Lightning Talk presentations This optional webinar for the proposer community was an additional chance to ask questions and get clarification on the ADVOCATE ISO. See the Special Notice ( ARPA-H-SN-26-148 ) for additional details.
ARPA-H anticipates that teaming will be necessary to achieve the goals of ADVOCATE. Prospective proposers are encouraged to form teams with varied technical expertise to submit a research proposal. To facilitate this process, we have created a teaming page where prospective proposers can share their profiles and learn more about other interested parties.
"What we are trying to achieve with ADVOCATE is a technology that can essentially serve as a clinician-extender: an autonomous agent smart enough to understand patients’ treatment needs, which can both provide certain care autonomously as well as engage the clinical team as needed." ARPA-H to revolutionize cardiovascular disease management with clinical agentic AI
Based on current listing details, eligibility includes: Not explicitly detailed, but implied to be for research and development teams capable of developing advanced AI systems for healthcare. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified, but described as a research and development funding opportunity. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
STOMP: Systematic Targeting Of MicroPlastics is a research grant from the Advanced Research Projects Agency for Health (ARPA-H) at HHS that funds multidisciplinary teams to develop methods for detecting, characterizing, and removing microplastics from the human body. The two-phase program will first develop lab-based measurement tools and image microplastics in animal tissue to understand toxicity mechanisms, then translate those tools into clinical settings and develop removal solutions. STOMP prioritizes protecting vulnerable populations including pregnant women, children, patients with chronic disease, and workers with high occupational exposure. Eligible applicants include academic institutions, nonprofits, and for-profit organizations. Total program funding is $144,000,000. Deadline is May 6, 2026.
PROactive Solutions for Prolonging Resilience (PROSPR) Program is sponsored by Advanced Research Projects Agency for Health (ARPA-H), U.S. Department of Health and Human Services (HHS). This program focuses on developing tools and therapies aimed at extending 'healthspan,' or the number of years people live in good health, by detecting and intervening on the earliest changes associated with aging.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
AAI Career Awards is a grant from the American Association of Immunologists (AAI) that honors members for outstanding research and career achievement. Through multiple award tracks — including the Lifetime Achievement Award, Distinguished Service Award, Distinguished Fellows program, Public Service Award, and Vanguard Award — AAI recognizes immunologists at every career stage who have made exceptional scientific, institutional, or public-policy contributions. Nominations originate from the AAI Council and designated committees. The program celebrates careers defined by scientific excellence, service to the immunology community, and contributions to public advocacy, minority recruitment in the sciences, and disease research. Deadline is September 10, 2025.